Assenagon Asset Management
APLS

Assenagon Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Assenagon Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,325
Closed -$1.63M – 1154
2025
Q1 		$1.63M Buy
74,325
+44,332
+148% +$1.22M ﹤0.01% 805
2024
Q4 		$957K Sell
29,993
-2,114,422
-99% -$63.6M ﹤0.01% 1109
2024
Q3 		$61.8M Buy
2,144,415
+1,409,707
+192% +$52.2M 0.11% 157
2024
Q2 		$28.2M Sell
734,708
-1,288,906
-64% -$58.4M 0.06% 228
2024
Q1 		$119M Sell
2,023,614
-121,390
-6% -$7.74M 0.28% 65
2023
Q4 		$128M Buy
2,145,004
+1,121,497
+110% +$56.9M 0.34% 54
2023
Q3 		$38.9M Buy
1,023,507
+524,797
+105% +$23.1M 0.12% 155
2023
Q2 		$45.4M Sell
498,710
-244,536
-33% -$21.1M 0.16% 113
2023
Q1 		$49M Buy
743,246
+15,517
+2% +$895K 0.17% 111
2022
Q4 		$37.6M Sell
727,729
-497,607
-41% -$26.4M 0.14% 149
2022
Q3 		$83.7M Buy
1,225,336
+341,898
+39% +$20.2M 0.32% 68
2022
Q2 		$39.9M Buy
883,438
+370,411
+72% +$16.9M 0.15% 133
2022
Q1 		$26.1M Buy
513,027
+445,745
+663% +$19.7M 0.07% 211
2021
Q4 		$3.18M Buy
+67,282
New +$2.65M 0.01% 658
2021
Q3 		– Sell
-235,775
Closed -$14.9M – 1279
2021
Q2 		$14.9M Buy
+235,775
New +$12.2M 0.05% 269
2020
Q4 		– Sell
-16,433
Closed -$496K – 1003
2020
Q3 		$496K Buy
+16,433
New +$491K ﹤0.01% 965
2019
Q4 		– Sell
-24,312
Closed -$586K – 758
2019
Q3 		$586K Buy
+24,312
New +$669K ﹤0.01% 672
2019
Q2 		– Sell
-308,992
Closed -$6.03M – 998
2019
Q1 		$6.03M Buy
+308,992
New +$4.86M 0.06% 273

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management's APLS Position: Q2 2025 in Review

Assenagon Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 74,325 shares — an estimated $1.63M sold.

Assenagon Asset Management first reported a position in APLS in Q1 2019 and held it in 18 quarters. The position peaked at $128M in Q4 2023. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • Assenagon Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 74,325 Apellis Pharmaceuticals shares in Q2 2025, an estimated $1.63M.
  • Assenagon Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 18 quarters.
  • Assenagon Asset Management's Apellis Pharmaceuticals position peaked at $128M in Q4 2023.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on Assenagon Asset Management's 13F filing for Q2 2025, filed 11 Jul 2025.